Accumulation of phosphorylated tau (pTau) is a key pathological feature of Alzheimer's disease (AD). pTau accumulation causes synaptic impairment, neuronal dysfunction and formation of neurofibrillary tangles (NFTs). The pathological actions of pTau are mediated by surrounding neuronal proteins, ...
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder characterized by brain aggregation of β-amyloid (Aβ) peptides and phosphorylated tau (P-tau) proteins. Extracellular vesicles (EVs) can be isolated and studied for potential roles in disease. While several studies have tested ...
Cerebrospinal fluid (CSF) phospho‐tau181 (p‐tau181) is an established biomarker of tangle pathology in Alzheimer's disease (AD), but does not detect aberrant tau phosphorylation in other tauopathies. Recently, tau phosphorylation at threonine7 (p‐tau217) was suggested to be a superior ...
Phosphorylated tauCerebrospinal fluidBackground: Memantine is a moderate affinity N-methyl-D-aspartate receptor antagonist approved for treatment of Alzheimer’s disease (AD). In AD, tau is abnormally hyperphosphorylated. However, no significant changes of phosphorylated tau levels in CSF are found at...
Fig. 1: Changes with age in plasma p-tau181 concentrations in Down syndrome and euploid controls. aAge-related changes in p-tau181 levels in individuals with Down syndrome (asymptomatic, prodromal Alzheimer’s disease and Alzheimer’s disease dementia, all in red) and in euploid controls (blue...
With the arrival of effective symptomatic treatments and the promise of drugs that may delay progression, we now need to identify Alzheimer’s disease
Tau pathology is known to spread in a hierarchical pattern in Alzheimer's disease (AD) brain during disease progression, likely by trans-synaptic tau transfer between neurons. However, the tau species involved in inter-neuron propagation remains unclear. To identify tau species respons...
Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules: A. del C. Alonso, I. Grundke-Iqbal and K. Iqbal. New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314 USA...
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome. Nat Commun. 2021;12(1):4304. doi:10.1038/s41467-021-24319-xPubMedGoogle ScholarCrossref 13. Janelidze S, Christian BT, Price J, et al. Detection of brain tau...
Development of tau-based therapies for Alzheimer’s disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inhe...